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scheme, prices of brand-name and generic drugs are to be set to the same level 
after the patent expires. METHODS: The data used for this study were extracted 
from the National Health Insurance Claims database. We established a monthly 
panel dataset pertaining to pharmaceutical consumption between January 2011 
and June 2013 (30 months). Proxies of market competition were considered as 
dependent variables such as price dispersion, market share of originators and 
relative ratio of utilization (originator/generics). Independent variables including 
policy effect, number of generic drugs, vintages of the first generic drugs, month 
for new generic entry and market value. RESULTS: The new pricing policy has 
resulted in no competition mechanism. Rather the policy shows more favorable 
to originators than generic drugs. Price dispersion has significantly decreased 
to 0.92 after the new pricing regulations. Market share of the originators has not 
significantly changed. However, originator-to-generic utilization ratio significantly 
increased to 6.12 (p< 0.001) after the new policy. This study offers different results 
to the government’s intention. CONCLUSIONS: Price competition cannot be suc-
cessfully achievable unless demand-side measures are combined. To lower prices, 
the bigger market share should be delivered through demand-side measures such 
as the reference pricing or compulsory substitution to lowest drugs applied in 
some European countries.
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OBJECTIVES: To approve a public price for a drug in Jordan, Jordan food and Drug 
association (JFDA) drug pricing committee ought to review the lowest price in the 
country of origin, the price of a predefined 13 countries and in KSA. In 2012, the 
evidence of cost-effectiveness (CE) was required to inform decisions of drug pricing. 
We sought to assess the role of CE studies in pricing drugs in Jordan. METHODS: A 
retrospective review of all applications submitted to the JFDA between November 
2013 to January 2015. RESULTS: The committee reviewed a total of 1,608 drug pric-
ing requests. Two hundred four were ricing new drugs, 369 were pricing local and 
international generics. The remainder was for pricing drugs previously registered in 
Jordan but renewed periodically as per policy. There was 11 enquires involving the 
use of CE studies. Applicants failed to correspond adequately to the committee and 
the committee often reconfirmed the requests more than one time. Median (IQR) 
of correspondences was 2 (3) times per case. These studies were non-comparative 
and concerning with establishing clinical efficacy. Median (IQR) ratio of the price 
proposed by applicants to the price of comparable substitute(s) was 1.7 (1.5). The 
prices were always negotiated downwards close to the price of the available sub-
stitutes. A premium price (i.e. +10% to 20%) was advocated to reward for added 
benefits such as convenience. CONCLUSIONS: The Jordanian pricing policies are 
comprehensive in responding to most of drug pricing applications. Decisions are 
straightforward with most comparisons made between drugs having similar clinical 
profiles. However, where CE evidence required there is no formal decision rules laid 
down, thus an official set of decision tools is warranted. This would include details 
of the perspective to be adopted, the comparisons to be made, form of economic 
evaluation and sources of data.
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OBJECTIVES: To compare the difference between the maximum retail price and 
tender price of brandname and generic drugs. METHODS: A large database analysis 
was used. The database was formed by merging two sub-databases, one was the 
tender prices of 94 antimicrobial drugs and circulatory system drugs collected from 
the centralized tendering of drug purchases across all the provinces(autonomous 
regions, municipality directly under the central government) of mainland China over 
the period of 2005-2013, the other was the corresponding maximum retail prices 
issued by the National Development and Reform Commission of China. The per-
centage differences between the maximum retail price and tender price (provincial 
average) was then calculated by year for antimicrobial drugs and circulatory system 
drugs, respectively. The generic-brandname ratio of the concerned percentage differ-
ences was also calculated. RESULTS: The percentage difference between maximum 
retail price and tender price for generic drugs was large, while the corresponding 
difference in brandname drugs was much smaller. The generic-brandname ratio 
of the concerned percentage differences increased from 1.7 in 2005 to 5.7 in 2013, 
except a mild decrease in 2009 and a moderate decrease in 2012. CONCLUSIONS: 
It may be the time to lift price control on drugs in China since the maximum retail 
price issued by the national government was too high as compared with tender 
price to exert effect on generic drugs, while for brandname drugs the maximum 
retail price was too close to tender price, which also consequentially diluted the 
significance of maximum retail price.  KEYWORDS: Maximum retail price; Tender 
price; Price reform; large database analysis. 
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OBJECTIVES: Canada has established Patented Medicine Prices Review Board 
(PMPRB) in 1987 with the objective of regulating prices of patented medicines sold 
in Canada to ensure prices are not excessive. When drugs’ prices meet the guide-
lines, they will be accepted; otherwise, the sponsor company will decrease them. The 
Employee Basic Medical Insurance (UEBMI) claims of Tianjin city from April 2008 
to March 2010 were used to compare the patients’ outpatient visit, total spending, 
drug spending, and OOP spending before and after the implementation of the EMP. 
The intervention group consisted of patients who visit the primary care institu-
tion which implemented EMP at least once before and after EMP and did not visit 
the control primary care institution which did not implement EMP, vice versa for 
the control group. A difference-in-difference approach was used to estimate the 
effects adjusting for patients’ socio-demographic characteristics and disease sever-
ity. Negative binomial regression was used to estimate the outpatient visit and tobit 
model was used to estimate the cost. RESULTS: Totally, 23362 patients from 49 
interventional primary care institution and 4148 patients from 42 control institution 
were involved in the study. The regression results showed that the annual patients’ 
outpatient visits (0.5%, p= 0.791) and the visits to primary care institution (0.2%, 
p= 0.951) had no change after implementing EMP compared to the control group. 
The patient’s average total spending (-0.6%, p= 0.850), drug spending (1.6%, p= 0.703) 
and OOP spending (0.4%, p= 0.883) did not change. The average total spending (2.9%, 
p= 0.443), drug spending (1.9%, p= 0.724) and OOP spending (1.2%, p= 0.722) in primary 
care institution was also not changed after implementing EMP. CONCLUSIONS: The 
EMP in Tianjin China was not associated with more outpatient visits in primary care 
institution and less medical spending, drug spending and OOP spending.
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OBJECTIVES: Beginning in 2014, the Affordable Care Act requires new health plans to 
cover essential health benefits (EHB), including pharmaceutical products, according 
to the state level benchmark plans. The objectives of this analysis were to understand 
state level variations in design of plans, access to drugs and likely impact on patient 
choice and health outcomes. METHODS: Benchmark plans for the top five states 
(i.e., FL, IL, NY, TX and CA), covering ~116 million lives, were obtained from the CMS. 
For each plan, the categories, classes and number of covered drugs was collected and 
pooled into one database. Analysis was conducted at the entire population level, state-
level and for top classes of drugs. The comments from patient groups were reviewed 
to understand the impact of EHB on patient choice and health outcomes. RESULTS: 
Benchmark plans for the top five states provide coverage of 4215 drugs belonging 
to 158 classes as defined by USP. While four states (FL, IL, NY and TX) had a similar 
number of covered drugs (median of 892 drugs), CA had a significantly lower number 
of covered drugs, amounting to 28% less than the other four states. On average, 10% 
of the drugs were in the class called “No USP Class”, highlighting the limitation of 
CMS designated USP classification system for the new plans. In CA, FL, IL, NY and 
TX there were 18, 7, 8, 11 and 8 classes, respectively, for which only 1 was covered. 
In CA, top 8 classes were identified for which patients had a 75% lower choice than 
other states, and these included indications such as Anti-Diabetics and Pain medi-
cations. CONCLUSIONS: Review of new benchmark plans shows some states can 
have a significantly lower patient choice of therapies. There is a need for new policy 
measures to ensure that all patients have equal access to new treatments.
PHP15
an assessmenT of THe THeraPeuTic biologic ProducTs licensed by THe 
fda and THe ema
Grozdanova A.1, Olasupo O.2, Seoane-Vazquez E.3
1Faculty of Pharmacy UKIM, Skopje Macedonia, Skopje, Macedonia, 2Massachusetts College of 
Pharmacy & Health Sciences, Boston, MA, USA, 3MCPHS University, Boston, MA, USA
OBJECTIVES: Therapeutic biologic products (BLA) are produced in living cell cul-
tures or through genetic engineering of proteins. The FDA BLA definition excludes 
allergenics, blood products, cellular and gene therapy, tissue products, and vaccines. 
This study assessed trends in BLAs licensed by the FDA and the European Medicines 
Agency (EMA) in the period 1995-2014. METHODS: Regulatory information for BLAs 
was derived from the agencies webpages. We extracted data for BLAs approved 
before the establishment of the EMA licensing process from the UK Medicines and 
Healthcare products Regulatory Agency (MHRA). Insulins and some hormones that are 
approved by the FDA using the drug application system, were excluded from analysis. 
BLA were classified using the WHO anatomical therapeutic chemical classification. 
Descriptive statistics and chi-square tests were conducted in the study. RESULTS: 115 
BLA were licensed by the FDA and the EMA in the period 1995-2014. The FDA licensed 
85.2% and the EMA 73.0% of the BLAs (p< 0.0001), with 22.6% of the BLAs licensed only 
by the FDA and 14.8% by the EMA. There were 5 BLA licensed by MHRA and the FDA. 
The EMA refused to license 4 BLAs. There were 62 BLAs (53.9% of the total) licensed by 
both agencies. The FDA licensed first 79.0% of the BLAs and the EMA 21.0%. The FDA 
licensed the BLAs in a median of 181 days before than the EMA. The largest number 
of BLAs corresponded to antineoplastic and immunomodulating agents (48.7% of 
BLAs), blood and blood forming organs (13.0%), and alimentary tract and metabolism 
(9.6%). CONCLUSIONS: The study found differences in the number of BLAs licensed 
by the FDA and the EMA. The FDA approved faster and licensed significantly more 
BLAs than the EMA. Future research should evaluate the effect in patient outcomes 
and cost of differences in BLAS availability in US and Europe.
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OBJECTIVES: This study aims to evaluate the impact of the new pricing policy 
implemented as of April, 2012 in South Korea on market competition among 
off-patent drugs since the reform has taken an objective to introduce market 
competition mechanisms among off-patent drugs. According to the new pricing 
